Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epratuzumab with Chemotherapy for Relapsed CD22-Positive ALL
NCT00098839Phase 2Completed
- Sponsor
- Children's Oncology Group
- Start
- Feb 2005
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label trial of epratuzumab in acute lymphoblastic leukemia (ALL), sponsored by Children's Oncology Group. Started Feb 2005; status: completed.
02
Drugs
epratuzumab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00098839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00098839.